Finally, despite the high interpatient heterogeneity largely described for SS, new explorations have discovered that PD-1 genomic status, as well as gene-driven CD39 expression (SNP_rs10748643), represent two novel genetic markers that are able to stratify SS patients by disease aggressiveness and potentially guide such patients to therapies. Here, ENTPD1 is linked to synovial sarcoma.